Prof. Dr. Stefan Pöhlmann

Date of birth 27.05.1970

Affiliation German Primate Center – Leibniz Institute for Primate Research,
Kellnerweg 4, 37077 Göttingen, Germany
Phone : +49/(0)3551-3851-150
E-mail : spoehlmann@dpz.eu

Current position Head of the Infection Biology Unit of the German Primate Center

Academic education

2004	Habilitation in Virology
1996-2000	Ph.D. thesis (summa cum laude) at the Institute of Clinical and Molecular Virology, University of Erlangen-Nürnberg, Erlangen, Germany, with Frank Kirchhoff, Ph.D.
1989-1996	Study of Biology, University of Erlangen-Nürnberg, Erlangen, Germany

Academic appointments

Since 2010	Head of the Infection Biology Unit, German Primate Center, and full professor at Georg-August-University Göttingen, Germany
2007-2010	Professor of Experimental Virology, Hannover Medical School, Germany
2003-2007	Head of a junior research group within SFB 466, Institute of Virology, University Erlangen-Nürnberg, Germany
2000-2003	Department of Microbiology, University of Pennsylvania, PA, USA. Postdoctoral fellow with Robert W. Doms, M.D., Ph.D.

Research interests

Host cell interactions of emerging viruses
Restriction factors
Non-human primate models for viral infections

Selected Funding

2022	EU consortium “Undine”
2021	COFONI - Coronavirus Research Network Lower Saxony
2020	BMBF - RENACO Project
2017	DARPA - Subproject in the Intercept Program
2012	Leibniz Graduate School for Emerging Infectious Diseases (EIDIS)

Professional Activities and Memberships

Member of the editorial board of Journal of Virology, Antimicrobial Agents and Chemotherapy, and Viruses
Academic editor for PLoS ONE
Deputy member of the Zentrale Kommission für die Biologische Sicherheit (ZKBS, Central Committee on Biological Safety)
Head of the Leibniz Graduate School Emerging Infectious Diseases,
Member of the COFONI steering committee

Awards

2011	AIDS Award of the H.W. & J. Hector foundation (jointly with G. Behrens and A. Kühl)
2002	Robert-Koch Post Doc Award, Robert-Koch Foundation, Germany

Ten most important publications

1. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, Cossmann A, Manger B, Baier E, Tampe B, Moerer O, Dickel S, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Winkler MS, **Pöhlmann S**, Hoffmann M. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. ***Lancet Infect Dis.*** 2022 22(6):766-767
2. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jäck HM, Behrens GMN, **Pöhlmann S**. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. ***Cell*** 2022 185(3):447-456
3. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N, Graichen L, Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, Jäck HM, Jahrsdörfer B, Schrezenmeier H, Müller M, Kleger A, Münch J, **Pöhlmann S.** SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. ***Cell*** 2021, 184(9):2384-2393
4. Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, Gassen NC, Müller MA, Drosten C, **Pöhlmann S**. Chloroquine does not inhibit SARS-CoV-2 infection of human lung cells. ***Nature*** 2020 585(7826):588-590
5. Hoffmann N. Kleine-Weber H, **Pöhlmann S**. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. ***Molecular Cell*** 2020 78(4):779-784.e5
6. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team, Hoffmann M, **Pöhlmann S**, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. ***Cell*** 2020 181(6):1436-1441
7. Hoffmann N, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, **Pöhlmann S**. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. ***Cell*** 2020 181(2):271-280
8. Kühl A, Münch J, Sauter D, Bertram S, Glowacka I, Steffen I, Specht A, Hofmann H, Schneider H, Behrens G, **Pöhlmann S.** (**2010**) Calcium-modulating cyclophilin ligand does not restrict retrovirus release. ***Nat Med*** 2010 16(2):155-6
9. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, **Pöhlmann S.** Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. ***Proc. Natl. Acad. Sci. USA*** 2005 102(22):7988-93
10. **Pöhlmann S**, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, Trowsdale J, Lee B, Coleman N, Doms RW. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and immunodeficiency viruses and activates infection in trans. ***Proc. Natl. Acad. Sci. USA*** 2001 98(5): p. 2670-5